

Supplemental Figure for:
 Immune-related adverse events by immune-checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer
 Hiroaki Akamatsu et al.

Supplementary Figure S1.

Comparison of serum proteins between irAE and non-irAE responders. (a) FGF-2, (b) IP-10, (c) MDC and (d) fold change of MCP-1. Each circle represents the data of individual patient. In FGF-2, one patient with asterisk represents lower value than detectable limit (FGF-2; 13.7 pg/mL).

